European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's ...

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...

Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...

Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

The U.S. Food and Drug Administration said on Friday it issued new labeling changes for testosterone products based on ...